Dr Steven M Martin joins the Isomerase Senior Management Team

 May 1st, 2016--Cambridge


We are pleased to announce that Dr. Steven M Martin has joined Isomerase as Chief Business Officer. He will join the senior management team, where his main role will be in taking the Isomerase business forward, especially new technologies. In addition, he will also have scientific input into certain partner projects, especially relating to scaled manufacture and the expanding Isomerase fermentation suite.

Steve was previously CEO of Zuvasyntha Ltd where he managed the growth and strategic refocusing of the company including securing major research collaborations with global industry partners, various rounds of seed investment and a merger with a US biotech company.

Prior to this Steve was R&D Director at TMO Renewables, where he was responsible for internal and external programs developing an industrial platform for the production of renewable fuels and chemicals. Whilst at TMO, he helped the Company raise more than £40m in funding and also set up and participated in more than twenty grant-funded collaborations with UK and overseas universities.

Prior to TMO, Steve was Head of Fermentation at Cubist Pharmaceuticals and was responsible for the UK pilot plant and the fermentation activities at two manufacturing sites. Steve’s technical background is in microbial fermentation, process optimisation and scale-up. He has taken processes from concept to commercialisation and most notably was lead fermentation scientist for the process development and scale-up of the first-in-class lipopeptide antibiotic daptomycin (Cubicin™). He has more than 20 years’ industrial experience in the development of microbial processes for applications in the pharmaceutical and industrial biotechnology sectors and has authored many peer reviewed scientific papers, articles and patents. Steve is also founding Director of Inspire Biotech Ltd and a visiting lecturer at the University of Bath.

Dr Matthew Gregory, CEO of Isomerase said “We are delighted that Steve has agreed to join us. He is a seasoned business professional with experience across a wide range of biotech companies. His addition to the senior management here really shows that Isomerase has laid firm foundations and is now focusing on continued growth and expansion of our business. Steve brings to Isomerase a great mix of commercial acumen and natural products experience – as demonstrated in the key role he had in developing the manufacture of daptomycin”.

“I am excited to join the first class team at Isomerase at a point in the Company’s evolution where it is poised for a major stage of growth” said Steve. “Their novel technologies have the potential to rapidly deliver a new generation of highly targeted effective natural product therapeutics, and I look forward to working with them to deliver on this vision”.